17 results about "Kidney ischemia" patented technology

The invention discloses a kidney blood perfusion device used before kidney ischemia, and relates to the field of perfusion devices, the kidney blood perfusion device comprises a machine shell, the side face of the machine shell is provided with a pair of fasteners, and the fasteners are used for fixing syringes respectively; the movable plate is arranged in the machine shell through a moving mechanism, and the moving mechanism can drive the movable plate to move in the machine shell; the pushing parts are arranged on the movable plate and used for pushing a piston handle in the injector, each pushing part comprises a sliding sleeve, a movable sleeve and an elastic component, the sliding sleeves are arranged on the side face of the movable plate, and the movable sleeves are inserted into the sliding sleeves in a sliding mode. The device has the advantages that manual time sequence errors in operation are avoided through double-stage strict separation, reperfusion after blood vessels are closed is ensured, a mechanical interlocking mechanism of a blocking pad and a stroke strip forcibly requires that perfusion can be started only after liquid bag expansion is completed, and the misoperation risk is completely eradicated from the hardware level; the double-stage seamless switching of liquid injection expansion and perfusion is realized, the efficiency is high, the perfusion speed of mechanical pushing injection during perfusion is more uniform, and the effect is better.

The present disclosure relates to a method for reducing or hindering development of renal ischemia-reperfusion injury in a subject the method comprising administering an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation.

The invention discloses application of a BTK inhibitor in preparation of a medicine for treating acute kidney injury and complications thereof. The invention provides a new strategy for treating acute kidney injury and complications thereof by using a BTK inhibitor, and particularly relates to application of the BTK inhibitor as an acute kidney injury medicine. The invention finds that serum creatinine and urea nitrogen levels can be effectively reduced by knocking out mouse BTK, and kidney injury is relieved and conversion from AKI to CKD is delayed or prevented by recovering kidney pathological structure and reducing apoptotic cell generation, which indicates that BTK is an effective target for treating acute kidney injury. Meanwhile, through treatment of an acute renal ischemia-reperfusion model, it is found that the BTK inhibitor such as ibrutinib can relieve ischemia-reperfusion induced renal function impairment and improve the renal function of a mouse, and it is indicated that the BTK inhibitor can serve as a treatment scheme for acute renal injury.

The invention relates to hypoxia response therapeutic VEGFA (vascular endothelial growth factor A) mRNA (messenger Ribonucleic Acid) and application thereof. The mRNA comprises a 5'end cap, a 5 'UTR (Untranslated Region) containing a Kozak sequence, VEGFA ORF (Open Region Fragment), a 3' UTR containing an RNA (Ribonucleic Acid) binding protein HuR binding site, a RhoBAST fluorescent aptamer at the tail end of the 3 'UTR and a PolyA tail. According to the design, through a HuR hypoxia-dependent nuclear plasma transport mechanism, the stability of mRNA in hypoxic cells is improved by 2.5 times, the protein expression quantity is improved by 2 times, and proliferation of endothelial cells is remarkably promoted. Further disclosed is a VEGFA mRNA delivery system based on engineered extracellular vesicles (EVs): EVs surface modified kidney targeting peptide LTH. The system is efficiently accumulated in ischemic kidneys, VEGFA expression is remarkably enhanced, and abnormal vascular hyperplasia of external renal organs is avoided. Animal experiments prove that the survival rate of a renal ischemia-reperfusion injury model can be increased to 100% by intravenous injection of drug-loaded EVs, and the capillary density is remarkably increased 7 days after treatment. The invention is suitable for treating ischemic diseases, organ ischemia reperfusion injury or chronic wounds and the like, and has the advantages of accurate targeting, hypoxia response, high stability and safety.

This invention discloses butylphthalide nanoparticles, comprising: a layered double hydroxide and butylphthalide, wherein the butylphthalide is loaded onto the layered double hydroxide. This invention also discloses a method for preparing the above-mentioned butylphthalide nanoparticles, comprising the following steps: mixing the layered double hydroxide, butylphthalide, and water, adsorbing, separating the solid and liquid phases, and drying to obtain butylphthalide nanoparticles. This invention further discloses the application of the above-mentioned butylphthalide nanoparticles in the preparation of drugs for treating acute renal ischemia-reperfusion injury. This invention also discloses a drug for treating acute renal ischemia-reperfusion injury, comprising: the above-mentioned butylphthalide nanoparticles and pharmaceutically acceptable excipients. The butylphthalide nanoparticles of this invention have high drug loading capacity, good stability, and can target and activate the PI3K-AKT signaling pathway, effectively inhibit HK-2 cell apoptosis and oxidative stress, restore mitochondrial function, and improve renal ischemia-reperfusion injury.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

The invention relates to the technical field of biological medicine, and particularly discloses a platelet membrane-coated mitochondrial compound and a preparation method and application thereof, and the platelet membrane-coated mitochondrial compound comprises mitochondria extracted from mammalian tissues and a platelet membrane coating the outer layer of the mitochondria. According to the present invention, the high kidney injury targeting enrichment rate is achieved through the PMITO compound constructed by coating the mitochondria with the platelet membrane, the healthy mitochondria is accurately delivered to the focus, and the energy crisis and the cell apoptosis are directly reversed; meanwhile, the biomimetic membrane structure can actively adsorb key inflammatory factors such as TNF-alpha and IL-1beta to synergistically realize dual mechanisms of energy repair and inflammation regulation, so that renal function indexes are remarkably improved in an animal model, and tissue pathological damage is relieved; finally, a new strategy for treating the renal ischemia-reperfusion injury, which is high in targeting property, clear in curative effect and good in biological safety, is formed.

The application discloses an application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicines.The application provides an application of the RNF130 activator in preparation of a medicine for preventing or treating kidney ischemia-reperfusion injury, and the RNF130 activator can improve kidney function of a mouse with kidney ischemia-reperfusion injury, improve levels of blood creatinine, urea nitrogen and cystatin C, reduce levels of kidney injury markers KIM-1 and LCN2, and reduce tubular injury, thereby playing a preventive and therapeutic role on kidney ischemia-reperfusion injury, and providing a new target for preparation of a medicine for preventing and treating acute kidney injury.

The present invention relates to a C-17 carbonyl-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C-17 carbonyl-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2 activator, and preparation of a medicament for treating / preventing diseases. The diseases comprise cerebral small vascular disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, schizophrenic cognitive impairment, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc., or other disease states and conditions which are obvious to a person skilled in the art. Also provided are a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutical composition containing same.

The present invention provides an acanthopanax injection for improving microcirculation and its preparation process. The preparation method includes: (1) extracting acanthopanax and performing solid-liquid separation to obtain a filtrate; (2) enriching and purifying the filtrate through an adsorption column to obtain the acanthopanax extract; the filler of the adsorption column includes silica gel and a ligand; the ligand is selected from straight-chain or branched-chain alkyl groups with C3-C18; mixing the acanthopanax extract with sodium chloride and activated carbon for injection, boiling to obtain a mixture, and filtering the mixture to obtain the acanthopanax injection. The present invention uses a reverse-phase adsorption column to enrich and purify the acanthopanax filtrate, which can effectively remove sensitizing substances such as tannins and polysaccharide macromolecules, and can retain the active ingredients to the greatest extent; the acanthopanax injection provided by the present invention can effectively improve microcirculation. Experiments show that it has a therapeutic effect on mice with an acute renal ischemic reperfusion model.

This invention discloses a renal hemoperfusion device for use before renal ischemia, relating to the field of perfusion devices. It includes a housing with a pair of fasteners on its side for securing a syringe to each; a movable plate, mounted within the housing via a moving mechanism that drives the movable plate to move within the housing; and a pair of pushers, both mounted on the movable plate, for pushing the piston handle in the syringe. Each pusher includes a sliding sleeve, a moving sleeve, and an elastic member. The sliding sleeve is located on the side of the movable plate, and the moving sleeve is slidably inserted into the sliding sleeve. The advantages of this invention are: strict separation of the two stages avoids human timing errors during operation, ensuring perfusion only after blood vessel closure; the mechanical interlocking mechanism between the baffle and the travel strip forces perfusion to begin only after the fluid-filled bladder has fully expanded, eliminating the risk of misoperation at the hardware level; seamless switching between the injection expansion and perfusion stages ensures high efficiency; and the mechanically pushed perfusion speed during perfusion is more uniform, resulting in better efficacy.

A C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2-Leap1 decoupling agent, and a use of the compound in the preparation of a medicament for preventing and / or treating diseases in a patient, the diseases comprising cerebral small vessel disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, cognitive impairment in schizophrenia, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc.

The present invention relates to a prophylactic or therapeutic agent for kidney disease. Provided are: a prophylactic or therapeutic agent for kidney disease, which contains AIM or a partial peptide thereof, or a nucleic acid that contains a nucleotide sequence encoding the AIM or the partial peptide thereof; or a method for screening for a prophylactic or therapeutic agent for kidney disease comprising using an animal obtained by subjecting a non-human mammal deficient in AIM expression to unilateral ureteral obstruction or transient renal ischemia / reperfusion.

The invention discloses a construction method and application of an exacerbated acute kidney injury model, and belongs to the technical field of biomedicine. In particular discloses application of an Atg7 phosphorylation deficient mutant Atg7-T82A / T562A in construction of an exacerbated acute kidney injury (AKI) model. The mutant is delivered to the kidney of a mouse through an adeno-associated virus (AAV), phosphorylation modification of AMPK on Atg7 is specifically blocked, and in combination with an acute renal ischemia (ARI) model, serum creatinine and urea nitrogen levels can be remarkably improved, renal tubular necrosis and apoptosis can be aggravated, autophagosome formation can be reduced, and mitochondrial injury can be induced. The method has high specificity and high efficiency, and provides a key tool for mechanism research, drug toxicity evaluation and treatment strategy development of autophagy-related renal injury.

This invention discloses a fluorescent probe for the specific detection of fatty acid amide hydrolases, its preparation method, and its applications, relating to the field of biomedical detection technology. The probe, named TMBID, has the structure shown in formula (I): (I). The structure includes a FAAH-specific recognition unit and a large Stokes shift red fluorophore. This probe has been demonstrated for the first time to selectively and sensitively visualize FAAH activity in renal cell carcinoma cells (ACHN, A498) and a renal ischemia-reperfusion injury (RIRI) model. In vitro experiments showed that TMBID's response to FAAH is not interfered with by other hydrolases (such as FAP-α, aminopeptidase N, etc.), and the URB597 inhibitor significantly suppressed the fluorescence signal by 67%. In cell experiments, TMBID could distinguish renal cell carcinoma cells (high fluorescence intensity) from normal kidney / hepatocytes (fluorescence intensity as low as 20%). Animal models confirmed its specific enrichment in renal cell carcinoma and RIRI tissues. This probe provides a revolutionary tool for early diagnosis of renal cell carcinoma, dynamic monitoring of renal injury, and FAAH-targeted therapy.

The invention relates to lactoferrin with high iron absorption capacity and a preparation method and application thereof. The iron saturation content of the lactoferrin with high iron absorption capacity is 10 mg / g or above. The lactoferrin with strong iron absorption capability prepared by the invention can quickly reduce the iron content in a microenvironment, and can better reduce iron to treat iron overload diseases, including but not limited to myocardial ischemia reperfusion, kidney ischemia reperfusion, cerebral infarction and other diseases; meanwhile, the better iron deprivation and antibacterial capacity is achieved.

To provide a composition for preventing or treating renal disorder, which has potential effectiveness against renal ischemia-reperfusion injury and related conditions.SOLUTION: The composition for prevention or treatment of renal disorder comprises microalgae.SELECTED DRAWING: None